摘要
目的探讨伊曲康唑与制霉菌素局部放药治疗外阴阴道假丝酵母菌病(VVC)患者的临床效果.方法 100例VVC患者,按照奇偶数法分为对照组和观察组,每组50例.对照组患者采取伊曲康唑治疗,观察组患者采取伊曲康唑联合制霉菌素局部放药治疗.观察比较两组患者治疗前及治疗1、3个月后的VVC评分及治疗效果、治疗3个月后实验室相关炎性指标.结果治疗3个月后,观察组患者的C反应蛋白(CRP)、白细胞计数(WBC)、降钙素原(PCT)分别为(4.58±1.37)mg/L、(5.49±1.24)×109/L、(0.16±0.11)μg/L,均明显低于对照组的(5.96±1.54)mg/L、(7.28±1.56)×109/L、(0.98±0.54)μg/L,差异均具有统计学(P<0.05);观察组患者治疗1个月后VVC评分(7.89±1.34)分、治疗3个月后VVC评分(4.28±0.38)分均明显低于对照组的(11.53±1.67)、(6.95±0.22)分,总有效率96.00%明显高于对照组的68.00%,差异均有统计学意义(P<0.05).结论对VVC患者采取伊曲康唑联合制霉菌素局部放药治疗的效果显著,能够明显改善临床症状及体征,减轻炎性指标,值得临床推广.
Objective To discuss the clinical effect of topical administration of itraconazole and nystatin in the treatment of vulvovaginal candidiasis (VVC) patients. Methods A total of 100 VVC patients were divided by odd-even number method into control group and observation group, with 50 cases in each group. The control group was treated with itraconazole, and the observation group was treated with topical administration of itraconazole and nystatin. Observation and comparison were made on VVC score before treatment and after 1 and 3 months of treatment, therapeutic effect and laboratory-related inflammatory markers after 3 months of treatment between the two groups. Results After treatment, the observation group had obviously lower -reactive protein (CRP), white blood cell count (WBC), procalcitonin (PCT) respectively as (4.58±1.37) mg/L,(5.49±1.24)×109/L and (0.16±0.11)μg/L than (5.96±1.54) mg/L,(7.28±1.56)×109/L and (0.98± 0.54)μg/L in the control group, and their difference was statistically significant (P<0.05). The observation group had obviously lower VVC score after 1 month of treatment as (7.89±1.34) points and (4.28±0.38) points after 3 months of treatment than (11.53±1.67) and (6.95±0.22) points in the control group. The observation group had obviously higher total effective rate as 96.00% than 68.00% in the control group, and their difference was statistically significant (P<0.05). Conclusion Topical administration of itraconazole and nystatin shows remarkable effect in the treatment of VVC patients, and it can obviously improve the clinical symptom and signs and reduce inflammatory indicators. It is worthy of clinical promotion.
作者
王润芝
阮秀云
WANG Run-zhi;RUAN Xiu-yun(Weihai Maternal and Child HealthHospital,Weihai 264200,China)
出处
《中国现代药物应用》
2019年第17期9-11,共3页
Chinese Journal of Modern Drug Application
